

Neutrophil Elastase - Pipeline Review, H2 2019

<https://marketpublishers.com/r/N0A744685076EN.html>

Date: December 2019

Pages: 65

Price: US\$ 3,500.00 (Single User License)

ID: N0A744685076EN

Abstracts

Neutrophil Elastase - Pipeline Review, H2 2019

SUMMARY

According to the recently published report 'Neutrophil Elastase - Pipeline Review, H2 2019'; Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Neutrophil elastase is a serine proteinase. It is secreted from neutrophils. It is involved in inflammatory diseases, including idiopathic pulmonary fibrosis, rheumatoid arthritis, adult respiratory distress syndrome, and cystic fibrosis. It modifies the functions of natural killer cells, monocytes and granulocytes. It inhibits C5a-dependent neutrophil enzyme release and chemotaxis.

The report 'Neutrophil Elastase - Pipeline Review, H2 2019' outlays comprehensive information on the Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics development with respective active and

dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Discovery stages are 6, 1 and 1 respectively.

Similarly, the universities portfolio in Discovery stages comprises 3 molecules, respectively. Report covers products from therapy areas Respiratory, Immunology, Genetic Disorders, Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Infectious Disease and Metabolic Disorders which include indications Cystic Fibrosis, Inflammation, Alpha-1 Antitrypsin Deficiency (A1AD), Bronchiectasis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bronchiolitis Obliterans, Chronic Obstructive Pulmonary Disease (COPD), Graft Versus Host Disease (GVHD), Ischemia Reperfusion Injury, Lung Disease, Lung Injury, Lung Transplant Rejection, Myelodysplastic Syndrome, Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair), Non-Alcoholic Steatohepatitis (NASH), Primary Ciliary Dyskinesia, Pulmonary Arterial Hypertension, Refractory Acute Myeloid Leukemia, Traumatic Brain Injury, Type 2 Diabetes and Vascular Injury.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)

The report reviews Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics and enlists all their major and minor projects

The report assesses Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Overview

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Companies

Involved in Therapeutics Development

AstraZeneca Plc

Chiesi Farmaceutici SpA

Chimerix Inc

Kyorin Pharmaceutical Co Ltd

LifeMax Laboratories Inc

pH Pharma Co Ltd

Proteo Inc

Santhera Pharmaceuticals Holding AG

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Drug Profiles

alvelestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CHF-6333 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dociparstat sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KRP-109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LM-030 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHP-303 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

POL-6014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sivelestat sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 to Inhibit ELANE for Immunology, Oncology and Respiratory Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ELANE for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Neutrophil Elastase for Lung Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tiprelestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Dormant Products

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Discontinued Products

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Product

Development Milestones

Featured News & Press Releases

Dec 10, 2019: Chimerix presents updated results from phase 2 clinical trial of DSTAT in refractory myelodysplastic syndrome and acute myeloid leukemia at American Society of Hematology Annual Meeting

Nov 13, 2019: LifeMax receives Orphan Drug Designation from the European Commission for LM-030 for the treatment of Netherton Syndrome

Sep 10, 2019: Santhera announces publication of phase I clinical data with POL6014 in Journal of Cystic Fibrosis

Jul 18, 2019: LifeMax receives rare pediatric disease designation for LM-030 for the treatment of netherton syndrome

Jun 27, 2019: LifeMax receives orphan drug designation from the United States Food & Drug Administration for LM-030 for the treatment of Netherton Syndrome

Nov 05, 2018: First patient dosed in phase 2 alpha-1 antitrypsin deficiency study

Oct 24, 2018: Santhera announces start of phase Ib/IIa trial with POL6014 in patients with cystic fibrosis

Oct 15, 2018: Santhera receives positive opinion for Orphan Drug Designation in the EU for POL6014 in Cystic Fibrosis

Sep 13, 2018: LifeMax appoints Laman Alani, Ph.D., as VP of Product Development

Jun 04, 2018: Cantex Pharmaceuticals Announces That Clinical Trial Data For CX-01 In Refractory Acute Myeloid Leukemia And Myelodysplastic Syndrome Will Be Presented At The 2018 ASCO Annual Meeting

Mar 12, 2018: Publication in Blood Advances Reports that the Combination of Cantex Pharmaceuticals CX-01 with Chemotherapy for the Treatment of Acute Myeloid Leukemia Showed Encouraging Complete Remission Rates and Rapid Platelet Count Recovery

Jan 03, 2018: Cantex Pharmaceuticals Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia

Jun 06, 2016: Polyphor successfully completes clinical Phase I study with POL6014 targeting life threatening lung diseases including cystic fibrosis

Jun 06, 2016: Proteo receives US\$ 1 million grant for a new Elafin drug formulation

Mar 23, 2016: Polyphor announces \$3 Million Award from Cystic Fibrosis Foundation Therapeutics to advance the clinical development of POL6014

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Chiesi Farmaceutici SpA, H2 2019
Pipeline by Chimerix Inc, H2 2019
Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019
Pipeline by LifeMax Laboratories Inc, H2 2019
Pipeline by pH Pharma Co Ltd, H2 2019
Pipeline by Proteo Inc, H2 2019
Pipeline by Santhera Pharmaceuticals Holding AG, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

AstraZeneca Plc

Chiesi Farmaceutici SpA

Chimerix Inc

Kyorin Pharmaceutical Co Ltd

LifeMax Laboratories Inc

pH Pharma Co Ltd

Proteo Inc

Santhera Pharmaceuticals Holding AG

I would like to order

Product name: Neutrophil Elastase - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/N0A744685076EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N0A744685076EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970